Get started
Author

John Byrd

Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
2024 · Ghayas C. Issa, Ibrahim Aldoss, et al. · Journal of Clinical Oncology · 252
Treatment of Relapsed Chronic Lymphocytic Leukemia: Old and New Therapies
2006 · J BYRD, T LIN, et al. · Seminars in Oncology · 31
Quantitative profiling of histone post-translational modifications by stable isotope labeling
2007 · A KNAPP, C REN, et al. · Methods · 25
Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.
2006 · Neil Kay, Susan Geyer, et al. · Blood · 24
Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
2020 · Matthew Cannon, Hannah Phillips, et al. · Journal of Clinical Medicine · 13
PDF
Challenges in Measuring Benefit of Clinical Research Training Programs—the ASH Clinical Research Training Institute Example
2014 · Lillian Sung, Mark Crowther, et al. · Journal of Cancer Education · 12
Abstract 828: DNA origami nanostructures as a targeted payload delivery system
2023 · Patrick Halley, Niksa Roki, et al. · Cancer Research · 2
Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model
2021 · Matthew Cannon, Hannah Phillips, et al. · Experimental Hematology and Oncology · 2
PDF
Chronic Lymphocytic Leukemia: Introduction
2006 · J BYRD, M GREVER · Seminars in Oncology · 2
RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA
2025 · Fieke Hoff, Alexander Li, et al. · Blood · 1
PDF
Poster session 6. Phase 1 studies
2013 · D. Pollyea, L. Gore, et al. · Annals of Oncology · 1
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma
2025 · Bettina Nadorp, Audrey Lasry, et al. · bioRxiv (Cold Spring Harbor Laboratory)
POSTER: AML-442 RAS Mutations Negate the Favorable Impact of NPM1 in Older Patients With Newly-Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA
2025 · Fieke Hoff, Ying Huang, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-442: RAS Mutations Negate the Favorable Impact of NPM1 in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA
2025 · Fieke Hoff, Ying Huang, et al. · Clinical Lymphoma Myeloma & Leukemia
Defining the role of Siglec-6-DOCK8 axis in cell adhesion and migration in Chronic Lymphocytic Leukemia
2021 · Jessica Judith Nunes, Ann Ventura, et al. · The Journal of Immunology
Evaluation of membrane bound IL-21 expanded natural killer cells for chronic lymphocytic leukemia therapy
2021 · Max Yano, J Rachel Lance, et al. · The Journal of Immunology
Novel role of B cell receptor signaling in regulation of Tcl1, an oncogene, and Par-4, a tumor suppressor gene, in B cell chronic lymphocytic leukemia (IRM10P.619)
2015 · Mary McKenna, Sunil Nooti, et al. · The Journal of Immunology
Constitutive IL-10 production by normal and malignant B-1 cells is dependent on B cell receptor signaling (IRM10P.620)
2015 · Sara Alhakeem, Mary McKenna, et al. · The Journal of Immunology
Withaferin A is effective in inhibiting the survival of B cell lymphomas and chronic lymphocytic leukemias (P2052)
2013 · Beth Gachuki, Karine Oben, et al. · The Journal of Immunology
Ibrutinib (PCI-32765) administration modulates a Th1 dominated immune response during cutaneous leishmaniasis infection (P3070)
2013 · Gayathri Natarajan, Jason Dubovsky, et al. · The Journal of Immunology
Toll-like receptor 2 ligands enhance monocyte Fcγ receptor function (68.16)
2012 · Prexy Shah, Steven Justiniano, et al. · The Journal of Immunology
A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.
2004 · Amy Johnson, Lisa Smith, et al. · Blood
Works count: 26
Citation count: 365
H-index: 6
I10-index: 6
Year
Topic
Type